

CURRICULUM VITAE

Rayna Kneuper Hall, M.D.

EDUCATION

Undergraduate: College of William & Mary, Williamsburg, Virginia
B.S. Biology - 1980

Medical School: Eastern Virginia Medical School, Norfolk, Virginia
M.D. - 1985

POSTGRADUATE TRAINING

Internship: Internal Medicine, 1985 - 1986
University of Texas Health Science Center at San Antonio

Residency: Internal Medicine, 1986 – 1988
University of Texas Health Science Center at San Antonio

Fellowship: Hematology/Oncology, 1988 – 1990
University of Texas Health Science Center at San Antonio

PROFESSIONAL LICENSES AND CERTIFICATION

Oncology: Certified 1993

Internal Medicine: Certified 1989

Medical License: South Carolina State
Texas

SPECIALTY CERTIFICATION

1987	Licensed to Practice Medicine, State of Texas
1989	Diplomate, American Board of Internal Medicine
1991	Licensed to Practice Medicine, State of South Carolina
1993, recertified	Diplomate, American Board of Internal Medicine (Medical Oncology)

ADMINISTRATIVE APPOINTMENTS

Medical Oncology Director
Hollings Breast Cancer Care Program
Medical University of South Carolina
1999-Present

Assistant Professor
Division of Hematology/Oncology, Department of Medicine
Medical University of South Carolina
1996-Present

Instructor
Division of Hematology/Oncology, Department of Medicine
Medical University of South Carolina
1991-1995

Instructor
Department of Medicine, Division of Oncology
University of Texas Health Science Center at San Antonio
1990-1991

PROFESSIONAL ORGANIZATION MEMBERSHIPS

American Society of Breast Disease
American Medical Association
American College of Physicians
American Society of Clinical Oncology
Christian Medical and Dental Society
South Carolina Medical Association
 Alternate Delegate for Charleston County 1999-2000
Charleston County Medical Society

BOARD MEMBERSHIPS

National Board of Medical Examiners

MEMBERSHIPS THROUGH MUSC

CALGB
NSABP

EXTRAMURAL GRANTS/AWARD AMOUNT

- HR# 4867 SmithKline Beecham; An Open-Label, Multicenter Study Evaluating the Efficacy and Safety of IV Kytril in the Prevention of Chemotherapy Induced Nausea and Vomiting. Project budget, 10/94 \$2,033.
- HR# 6399 SmithKline Beecham; A Double Blind, Multicenter, Parallel Study Comparing the Efficacy and Safety of Oral Granisetron HCL 2 mg with IV Ondansetron HCL 32 mg, Given Once, in the Prevention of N&V Induced by IV Cyclophosphamide Based or Carboplatin-Based Chemotherapy in Patients with Malignant Disease. Project budget, 6/95 \$32,200.
- HR 4206 SmithKline Beecham; A Double Blind, Parallel, Multicenter Study Comparing the Efficacy and Safety of IV Granisetron and Ondansetron in the Prophylaxis of Nausea and Emesis Induced by Cisplatin Based Chemotherapy. 7/92 \$36,960.
- HR 4254 SmithKline Beecham; A Double Blind, Parallel, Multicenter Study in Patients with Malignant Disease Who Receive IV Granisetron 10 mg/kg or 40 mg/kg to control Nausea and Vomiting During Multiple Cycles of Highly Emetogenic, Cisplatin Based Chemotherapy. 8/92 \$66,456.
- HR 4312 SmithKline Beecham; A Double Blind Comparison of the Efficacy and Safety of Oral Granisetron (1 mg BID) with Oral Prochlorperazine (10 mg BID) in Preventing Nausea and Emesis in Patients Receiving Moderately Emetogenic Chemotherapy. 10/92 \$43,740.
- HR 4367 Zeneca Pharma; A Randomized Multicenter, Efficacy and Safety Study to Evaluate Arimidex 1 and 10 mg Double Blind, Compared to Open Label Megace in Postmenopausal Women with Advanced Breast Cancer. 01/19/93.
- NCI TRC-9801 AA Multicenter, Expanded Access, Open Label, Safety Study of Recombinant Humanized Anti-p185 Monoclonal Antibody (rhuMA6 HER2) In Patients with HER2 Overexpression Who Have Relapsed Following Two Cytotoxic Chemotherapy

Regimens for Metastatic Breast Cancer@ National Cancer Institute, 1998.

Charleston RACE FOR THE CURE. Susan G. Komen Breast Cancer Foundation. Grant Award: Breast Cancer Education and Information Program. 1997 \$5,000

HR 9838 Co-Investigator, Sponsored by the Department of Defense. Real-Time PCR Analysis of Peripheral Blood: A Non-Invasive Technology That Can Be Used to Assess Tumor Burden in Breast Cancer Patients. 2003

PROTOCOLS (MUSC Principal Investigator)

- CALGB 9082 A Randomized, Comparative Study of High Dose CPA/cDDP/BCNU and ABMS versus Standard Dose CPA/cDDP/BCNU as Consolidation to Adjuvant CAF for Patients with Operable Stage II or Stage III Breast Cancer Involving > 10 Axillary Lymph Nodes. 01/20/91
- CALGB 9343 Lumpectomy, tamoxifen & irradiation of breast vs lumpectomy plus tamoxifen in women > 70 with breast cancer. 07/15/94
- CALGB 9394 Hi-Dose Cyclophosphamide/Adriamycin in newly diagnosed breast cancer. 06/15/95
- CALGB 9484 Linkage of molecular & epidemiological breast cancer with treatment data. 06/15/95
- CALGB 9741 Sequential Chemo Using Doxorubicin, Paclitaxel & Cyclophosphamide in lymph node positive breast cancer. 09/15/97
- CALGB 9840 Paclitaxel Via Weekly vs Standard (Q3 wks) infusion in Met. Breast Cancer. 11/17/98
- CALGB 49802 Phase III Study of Adriamycin/Taxotere vs. Adriamycin/Cytoxan for Node Positive or High Risk Node Negative Breast Cancer. 06/01/99
- CALGB 49805 A Phase III Randomized Double Blind Study of Letrozole versus Placebo in Women with Primary Breast Cancer Completing Five or More Years of Adjuvant Tamoxifen (NCIC CTG MA.17). 06/01/99
- CALGB 7980 Impact of Easy-to-Read Informed Consent Statements. 07/30/99

CALGB 9872	Activated Protein C Resistance and Tamoxifen-Associated Thrombosis. 01/15/99
MUSC4135	Bartels Pharm; Chemoresponse Assay for Determination of Tumor Sensitivity to Chemotherapeutic Drugs. 01/01/92 - 09/30/92 \$10,000.
MUSC 4940	Roberts Pharmaceuticals: An Open Protocol for the use of Anagrelide for Essential Thrombocytosis. 07/19/94
MUSC 4966	Rhone Poulenc-Rorer: Phase III Comparison of Taxotere & Taxol as Second Line for Progressive Metastatic Disease. APP: 08/16/94
MUSC 6070	High Dose Tamoxifen and Cisplatin...Ovarian Cancer. 10/18/94
MUSC 7077	Anastrozole vs Tamoxifen 1 st Line Therapy Advanced Breast Cancer Postmenopausal. 01/21/97
MUSC 7151	Arimidex vs Nolvadex vs Arimidex + Nolvadex Post-Menopausal Breast Cancer. Zeneca Inc. \$37,300 03/17/97
MUSC 7768	Phase II Trial of Multitargeted Antifolate (MTA) in Locally Advanced Metastatic Breast Cancer. Eli Lilly. 09/15/98
MUSC 7791	Comparison of effect of SCH57050 & Anastrozole in Breast Cancer. Schering-Plough. 07/21/98
NSABP B-30	A 3-Arm Randomized Trial to Compare Adjuvant Adriamycin and Cyclophosphamide Followed by Taxotere (AC-T); Adriamycin and Taxotere (AT; and Adriamycin, Taxotere, and Cyclophosphamide (ATC) in Breast Cancer Patients with Positive Auxiliary Lymph Nodes. 01/12/99
CALGB 9872	Activated Protein C Resistance and Tamoxifen-Associated Thrombosis. 04/20/99
CALGB 49802	Phase III Study of Adriamycin/Taxotere vs. Adriamycin/Cytosan for the Adjuvant Treatment of Node Positive or High Risk Node Negative Breast Cancer. 05/18/99
MUSC 8330	A Randomized Study of Counseling Interventions for BRCA-1/BRCA-2 Cancer Susceptibility Testing. 05/18/99
CALGB 79802	A Randomized, Controlled Trial to Evaluate the Impact of Easy-to-Read Informed Consent Statements. 07/30/99

MUSC 8520 Phase II Study of Gemcitabine and CPT-11 (Irinogem) in previously Treated Metastatic Breast Cancer. 08/17/99

CALGB 79804 Issues of Survivorship Among Breast Cancer Survivors. 01/18/00

CALGB 49906 A Phase III Study of Doxorubicin-Cyclophosphamide Therapy Followed by Paclitaxel or Docetaxel Given Weekly or Every 3 Weeks in Patients with Axillary Node-Positive or High Risk Node Negative Breast Cancer. 02/15/00

CALGB/SWOG 9831 Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel With or Without Trastuzumab as Adjuvant Treatment for Women with HER-2 Overexpressing or Amplified Node Positive or High-Risk Node Negative Breast Cancer. 10/17/00

CTO 100315 Open-Label, Multicenter Trial of Femera (Letrozole) 25 mg as First Line Therapy in Post-Menopausal Women with Metastatic Breast Cancer Relapsing Following Adjuvant Tamoxifen Therapy. 06/12/01

NCIC CTG MA.17 A Phase III Randomized Double Blind Study of Letrozole Versus Placebo in Women with Primary Breast Cancer Completing Five or More Years of Adjuvant Tamoxifen. 04/23/02

CTO 100613 A Phase II Study of Neoadjuvant Docetaxel and Vinorelbine Followed by Surgery and Then Doxorubicin and Cytoxan in Women with Stage IIB and Stage III Breast Cancer. 04/24/02 TNAC

CTO 100621 A Phase II iStudy of Neoadjuvant Taxotere/Navelbine Plus Herceptin Followed by Adjuvant Adriamycin and Cytoxan in Women with HER-2 Overexpressing Locally Advanced Breast Cancer. 04/24/02 TNAC-H

CTO 100707 A Multicenter Phase II Randomized Study of RPR 116258 Administered as a 1-Hour Intravenous Infusion Every Three Weeks in Taxoid Resistant Metastatic Breast Cancer Patients. 03/11/03

CTO 100705 An Open-Label, Randomized, Multicenter Study to Evaluate the Use of Zoledronic Acid in the Prevention of Cancer Treatment-Related Bone Loss in Postmenopausal Women with ER+ and/or PR+ Breast Cancer receiving Letrozole as Adjuvant Therapy. 06/05/03

SWOG 40101 Cyclophosphamide and Doxorubicin (CA) (4 vs 6 Cycles) Versus Paclitaxel (4 vs 6 Cycles) as Adjuvant Therapy For Women with Node-

Negative Breast Cancer: A 2X2 Factorial Phase III Randomized Study. 06/05/2003

- CTO 100749 A Randomized, Placebo-Controlled, Double-Blind Trial Evaluating the Effect of Exemestane in Clinical Stage T1-2 N0-1 M0 Postmenopausal Breast Cancer Patients Completing At Least Five Years of Tamoxifen Therapy. 06/05/2003
- CTO 100088 Myeloproliferative Disorder – Anagrelide in Thrombocytosis
- CTO 100120 A Double-Blind, Multicenter, Parallel Study Comparing the Efficacy and Safety of Oral Granisetron Hydrochloride 2mg with IV Ondansetron Hydrochloride 32mg, Given Once, in the Prevention of Nausea and Vomiting
- CTO 100813 A Phase III Randomized, Placebo-Controlled, Double-Blind Study of Oral CCI-779 Administered in Combination with Letrozole vs. Letrozole Alone as First Line Hormonal Therapy in Postmenopausal Women with Locally Advanced or Metastatic Breast Cancer. Principal Investigator. 09/22/2004 – Active (Wyeth)
- CTO 100797 A Randomized, Open-Label, Phase III Study of RPR 109881 IV Every 3 Weeks Versus Capecitabine (Xeloda) Tablets Twice Daily for 2 Weeks in 3-Week Cycles in Patients with Metastatic Breast Cancer Progressing After Taxanes and Anthracycline Therapy. Principal Investigator. 04/27/2004 – Active (Aventis)
- CTO 100881 A Clinical Trial comparing Anastrozole With Tamoxifen in Postmenopausal Patients With Ductal Carcinoma In Situ (DCIS) Undergoing Lumpectomy With Radiation Therapy. Principal Investigator. 03/30/2005 – Active (NSABP)
- CTO 100311 A Multicenter, Open-Label, Phase III, Randomized, Active-Controlled Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of rhuMab CEGf (BevaCizumab) in Combination with Capecitabine Chemotherapy. In Subjects With Previously Treated Metastatic Breast Cancer. Principal Investigator. 03/20/2001 – Active (Genentech)

Collaborator on Study “Promoting Positive Adaptation Among Breast Cancer Survivors and Their Families: Development of an Evidence-Based Intervention.” 2002 – 2004 with Institute of Psychiatry and Department of Radiation, MUSC

Collaborator on Study “Variant ErbB2 allele (1170 Pro) in HER-2/neu FISH Amplified Breast Cancers” with Christopher Benz, Ph.D. University of California at San Francisco and the Buck Institute for Age Research

ACADEMIC COMMITTEE ACTIVITIES

University: - Institutional Review Board for Human Research (IRB) July 1995 - October 2000
- Cancer Committee (VA) 1992 - 1999
- Physician Recognition Committee (VA) 1996

Department: - Faculty Productivity Committee May 18, 1995 - October 19, 1995
- Quality Assurance/Performance Improvement 1994 - 1998

Division: - Quality Assurance Evaluation Projects for VA 1992 - 1994
- Cancer Patient/Family Support Group Committee

Hollings Cancer Center: - Clinical Research Committee 1996 - Present
- Medical Oncology Director, Hollings Breast Cancer Care Program, 1998 – Present

Ralph H. Johnson VAMC: - Hospice Committee – Chairman (VA) 1992 - 1999
- Pharmacy & Therapeutics Committee (P&T) November 2002 – Present

MAJOR TEACHING RESPONSIBILITIES

Undergraduate Medical Education:

- B.S. Students - Annual lectures on breast cancer - 1992, 1994, 1995
- Medical Students - Attending on Hematology/Oncology Consult Services at MUH, CMH, VA -- six months/year, 1991 – 2004; VA Hem/Onc Consult 12 months/year 06-2004 - Present
- Attending on General Medicine Service at VA -- 1-3 months/year 1991 - 2004
- Physical Diagnosis Courses - 1992 - 1998, 2000 - 2002
- Junior Core Quarterly Lecture Series; Solid Tumors - 1991 - Present
- Internal Medicine Small Group Preceptor: Spring 1999, Fall 2000
- Faculty/Student Mentoring Program – 2000 - Present

Graduate Medical Education:

- Fellows - Consult Services at MUH, CMH and VA -- 12 months per year
- Outpatient clinics at Hollings Cancer Center and at VA each week
- Direct Journal Clubs on Breast Cancer, Anthracyclines, Supportive Care, Hormonal Therapy
- Faculty/Fellow Mentoring Program - 1999 - Present
- Residents/Interns - Consult Services at MUH, CMH and VA 12 months per year
- Weekend Call on Inpatient Service - 1-2
- Lecture Series; Breast Cancer - 1991 - 2002
Oncologic Emergencies - 1993 - 2005

Graduate Studies Education:

- Pharm. D. Students - Annual lectures on breast cancer - 1992 - 2001
Prostate Cancer – 1994
- Advisor to Students: Russell Jenkins, John Lucas, and Chelsea Rainwater

Continuing Medical Education

- October 6, 1992 - Grand Rounds “**NON-INVASIVE BREAST CANCER**”
- Weekly Breast Cancer Clinic Conference - Hollings Cancer Center - 1992 - Present
- Spring 1994 - Oncology Nursing Society “**ANTIEMETICS**”
- January 7, 1997 - Medicine Grand Rounds “**BREAST CANCER: RECENT ADVANCES IN DIAGNOSIS AND THERAPY**”
- Introduction to Clinical Medicine, 1997
- February 5, 1999 - South Carolina Nurse Practitioners Conference “**APPROACHING THE NEW MILLENNIUM: EXCITING ADVANCES IN THE DIAGNOSIS AND MEDICAL MANAGEMENT OF BREAST CANCER**”
- February 9, 1999 - Conway Regional Medical Center “**BREAST CANCER UPDATE**”
- January 11, 2000 - Grand Rounds “**COUNSELING YOUR PATIENTS REGARDING BREAST CANCER RISK**”

- March 28, 2000 - Medicine Research Grand Rounds - MUSC **“ADVANCES IN THE DIAGNOSIS, TREATMENT AND PREVENTION OF BREAST CANCER”**
- April 4, 2000 - Low Country Area Health Education Center Tricounty Medical Society - Allendale, SC **“BREAKTHROUGHS IN THE DIAGNOSIS, TREATMENT, AND PREVENTION OF BREAST CANCER”**
- October 24, 2000 - Palmetto Baptist Medical Center Grand Rounds - Columbia, SC, **“BREAST CANCER: RISK CALCULATION AND RISK REDUCTION”**
- January 23, 2001 - Ralph H. Johnson VA Hospital - Charleston, SC **“BREAST CANCER: DIAGNOSIS, TREATMENT AND PREVENTION”**
- August 11, 2002 – Women in Oncology – Duke University Consortium Charleston, South Carolina **“UPDATE IN BREAST CANCER DIAGNOSIS AND TREATMENT”**
- Women in Oncology Conference - Charleston, SC **“SYSTEMIC TREATMENT OF BREAST CANCER”**
August 11, 2001
- South Carolina Oncology Society Annual Meeting – Charleston, SC **“ADJUVANT THERAPY FOR BREAST CANCER: UNRAVELING MYSTERIES AND RESOLVING CONTROVERSIES”**
September 6, 2002
- Medical Grand Rounds, MUSC, **“ENDOCRINE THERAPY OF BREAST CANCER: THE NEARLY FORGOTTEN HERO(INE)”**
May 20, 2003

CLINICAL INTERESTS AND RESPONSIBILITIES

- Interests:**
- Breast Cancer - Prevention, Evaluation and Management
 - Supportive Cancer Care - Antiemetics, Pain Control, Nutrition, Treatment Toxicities
- Responsibilities:**
- Review NSABP and SWOG and Industry Breast Cancer Protocols for consideration for opening at Hollings Cancer Center
 - Participate in Breast Conference each week - Hollings Cancer Center

RESEARCH COLLABORATION

1. **Rayna Kneuper Hall**, Suzanne O'Neill – Institute of Psychiatry. “The Prediction of Benefit Finding and Experience of Distress in Newly Diagnosed Breast Cancer Patients.” Family Medicine Journal, Volume 36 Issue 1, January 2004, pp. 35-39.

INVITED PRESENTATIONS

- CIBA-GEIGY ONCOLOGY DIVISION
“**OVERVIEW OF HISTORY OF MEDICAL ONCOLOGY**”
Morristown, New Jersey
July 19, 1990
- I Can Cope Series
American Cancer Society
“**LIVING WITH CANCER**”
Spring, 1992
- MEDICINE GRAND ROUNDS
Medical University of South Carolina
“**NON-INVASIVE BREAST CANCER**”
October 6, 1992
- Oncology Nursing Society
“**ANTIEMETICS IN CANCER CARE**”
Spring, 1994

- VA Clinical Research Session
“BREAST CANCER CARE”
 May 28, 1996
- MUSC Fellows Reunion Weekend
 Formal Presentation
“BREAST CANCER - - 10 YEARS UPDATE”
 June 29, 1996
- First Annual Memorial Medical Center
 Cancer Congress
“OVERVIEW OF BREAST CANCER CARE”
 Savannah, GA
 September 20, 1996
- Orangeburg Regional Cancer Conference
“UPDATE ON BREAST CANCER”
 Orangeburg, SC
 October 29, 1996
- First Annual Women’s Health Fair
 Breast Cancer Conference
 January 21, 1997
- Annual Emergency Lecture Series
 Oncologic Emergencies
 July, 1997 - Present
- MEDICINE GRAND ROUNDS
 MUSC
“BREAST CANCER: RECENT ADVANCES IN DIAGNOSIS AND THERAPY”
 January 7, 1997
- HCC and New Life Assembly of God Church
 Breast Health Seminar Series
**“IMPORTANCE OF EARLY DETECTION OF BREAST CANCER: SIGNS,
 SYMPTOMS AND STATISTICS”**
 April 18, 1998
- South Carolina Nurse Practitioners Conference
**“APPROACHING THE NEW MILLENNIUM: EXCITING ADVANCES IN THE
 DIAGNOSIS AND MEDICAL MANAGEMENT OF BREAST CANCER”**
 February 5, 1999

- Conway Regional Medical Center
“BREAST CANCER UPDATE”
 February 9, 1999
- Susan G. Komen Foundation Fundraiser Luncheon
 For the **“RACE FOR THE CURE”**
 Keynote Speaker
 October 14, 1999
- San Antonio Breast Cancer Symposium - Poster Presentation
**“LIPOSOMAL DOXORUBICIN-INDUCED CUTANEOUS ERUPTION MIMICS
 GRAFT-VS-HOST DISEASE”**
 December 11, 1999
- MEDICINE GRAND ROUNDS - MUSC
“COUNSELING YOUR PATIENTS REGARDING BREAST CANCER RISK”
 January 11, 2000
- Medical Specialty Services Quarterly Retreat
**“EXCITING DEVELOPMENTS IN BREAST CANCER DIAGNOSIS,
 TREATMENT AND PREVENTION”**
 February 08, 2000
- Medicine Research Grand Rounds - MUSC
**“ADVANCES IN THE DIAGNOSIS, TREATMENT AND PREVENTION OF
 BREAST CANCER”**
 March 28, 2000
- Low Country Area Health Education Center
 Tricounty Medical Society
**“BREAKTHROUGHS IN THE DIAGNOSIS, TREATMENT, AND PREVENTION
 OF BREAST CANCER”**
 Allendale, SC
 April 4, 2000
- Poster Presentation for the American Society of Clinical Oncology (ASCO) - New Orleans, LA
**“INTRANASAL CALCITONIN AMELIORATES ARTHRALGIAS/MYALGIAS
 ASSOCIATED WITH TAXANE CHEMOTHERAPY”**
 May 22, 2000
- Emergency Lecture Series for New Interns
“ONCOLOGIC EMERGENCIES”

August 22, 2000

- The Stella Maris Women's Club – Sullivan's Island, SC
"OVERVIEW OF BREAST CANCER DIAGNOSIS TREATMENT AND PREVENTION"
October 9, 2000
- Palmetto Baptist Medical Center Grand Rounds - Columbia, SC
"BREAST CANCER: RISK CALCULATION AND RISK DEDUCTION"
October 24, 2000
- San Antonio Breast Cancer Symposium - San Antonio, TX
"EARLY RECOGNITION OF TAXANE-ASSOCIATED CANALICULITIS IMPORTANT IN PRESERVING LACRIMAL DUCT FUNCTION"
December 7, 2000
- Second Annual Issues in Women's Health Conference
Charleston, SC
"BREAST CANCER OVERVIEW OF STATISTICS, RADIOGRAPHIC AND CLINICAL PRESENTATIONS, RISK ESTIMATION, AND PREVENTION"
April 16-18, 2001
- Women in Oncology Conference - Charleston, SC
"SYSTEMIC TREATMENT OF BREAST CANCER"
August 11, 2001
- San Antonio Breast Cancer Symposium – San Antonio, TX
"HIGHER BIRTH-WEIGHTS MAY BE RELATED TO INCREASED RISK OF AGGRESSIVE CANCER IN YOUNG AFRICAN-AMERICAN WOMEN"
December 11, 2001
- South Carolina Oncology Society Annual Meeting – Charleston, SC
"ADJUVANT THERAPY FOR BREAST CANCER: UNRAVELING MYSTERIES AND RESOLVING CONTROVERSIES"
September 6, 2002
- San Antonio Breast Cancer Symposium – San Antonio, TX
"PSEUDOMONAS AERUGINOSA SUBUNGAL INFECTIONS ASSOCIATED WITH WEEKLY TAXANE CHEMOTHERAPY"
December 13, 2002
- Medical Grand Rounds, MUSC, **"ENDOCRINE THERAPY OF BREAST CANCER: THE NEARLY FORGOTTEN HERO(INE)"**

November 17, 2006

May 20, 2003

- Women In Oncology, The Mills House, Charleston, SC, “
- 26th Annual San Antonio Breast Cancer Symposium Presentations submissions, **“COMPARATIVE ANALYSIS OF PATIENT DEMOGRAPHICS AND TUMOR CHARACTERISTICS FROM HER-2/NEU AMPLIFIED FISH DATABASE AND MUSC TUMOR REGISTRY DATABASE”**
December 6, 2003
- 26th Annual San Antonio Breast Cancer Symposium Presentations submissions, **“HER-2/NEU INTRATUMORAL HETEROGENEITY AS ANALYZED BY FISH: A NON-APPARENT ENTITY EXCEPT IN MIXED HISTOLOGY TUMORS”**
December 6, 2003
- 40th Annual Meeting of the American Society of Dermatopathology, **“POLYETHYLENE GLYCOL (PEG)-LIPOSOMAL DOXORUBICIN-RELATED CUTANEOUS ERUPTION: TWO NEW HISTOLOGIC PATTERNS”**
Investigator along with Francois Cady, M.D. and John Metcalf, M.D.
October 9 – 12, 2003 Chicago
- American Medical Women’s Association, Student Division, **“STAYING SPIRITUALLY ANCHORED IN THE TUMULT OF MEDICINE”**
March 2, 2004
- 28th Annual San Antonio Breast Cancer Symposium
December, 2005

PUBLICATIONS

1. Brown T, Kuhn J, Marshall M, Rodriguez G, **Kneuper R**, Cagnola J, Von Hoff D. A phase I clinical and pharmacokinetics trial of liposomal doxorubicin (NSC 620212). Proc Am Soc Clin Oncol, 10:93, 1991.
2. Rodriguez G, Havlin K, Burris H, Wall J, Shaffer D, Smith L, Kalter S, Brown T, Cangola J, Weiss G, **Kneuper Hall R**, Von Hoff D. Phase I clinical trial of ilmofosine, a novel antitumor agent. Proc Am Soc Clin Oncol, 10:114, 1991.
3. Wall J, Burris H, Von Hoff D, Rodriguez G, **Kneuper Hall R**, Shaffer D, O'Rourke T, Brown T, Weiss G, Clark G, McVea S, Brown J, Johnson R, Freidman C, Smith B, Mann W, Kuhn J. A phase I clinical and pharmacokinetic study of the

November 17, 2006

- topoisomerase I inhibitor topotecan (SK & F 104864) given as an intravenous bolus every 21 days. *Anti-cancer Drugs*, 3: 337-345, 1992.
4. Hall PD, **Kneuper Hall R.** Letter to Editor. *Annals of Pharmacotherapy*, 1995: 29:941.
 5. Hall PD, Leshner BA, and **Kneuper Hall R.** Adjuvant Therapy of Node-Negative Breast Cancer. *Annals of Pharmacotherapy*, 1995: 29:289-298.
 6. Hall PD, Self SE and **Kneuper Hall R.** Interaction of Maintenance Interferon with Cytolytic Cells in Multiple Myeloma Patients Who Have Responded to Cytotoxic Chemotherapy. *Annals of Pharmacotherapy*, 1997: 17:248-255.
 7. Buzdar Aman U and **The Arimidex Study Group.** Anastrozole versus Megestrol Acetate in the Treatment of Postmenopausal Women with Advanced Breast Carcinoma: Results of a Survival Update Based on a Combined Analysis of Data from Two Mature Phase III Trials. *Cancer*, September 15, 1998, Volume 83, Number 6: 1142-1152.
 8. Burtness B, Windsor S, Holsten B, DiStasio S, Staugaard-Hahn C, Abrantes J, **Kneuper Hall R**, Farber L, Orell J, Bober-Sorcinielli K, Haffty BG, and Reiss M. Adjuvant Sequential Dose Dense Doxorubicin Paclitaxel and Cyclophosphamide (ATC) for High-Risk Breast Cancer is Feasible in the Community Setting. *European Journal of Cancer*. (In Press)
 9. Marley EM, Kallab AM, and **Kneuper Hall R.** Anastrozole Associated Psychosis in a Patient with Metastatic Breast Cancer. *American Journal of Clinical Oncology*. (In Press)
 10. **Kneuper Hall R.**, Metcalf J. Liposomal Doxorubicin-Induced Cutaneous Eruption Mimics Graft-VS-Host Disease. *Breast Cancer Research and Treatment* 57:1; 516 November, 1999.
 11. **Kneuper Hall R.**, Marshall M. Intranasal Calcitonin Ameliorates Arthralgias/Myalgias Associated with Taxane Chemotherapy. *Proc Am Soc Clin Oncol* 19:2453, 2000.
 12. **Kneuper Hall R.**, Metzner-Sadurski JK., Marshall M., Howard GR. Early Recognition of Taxane Associated Canaliculitis Important in Preserving Lacrimal Duct Function. *Breast Cancer Research and Treatment*. 64:1; 356, November, 2000.

13. Ferguson P., Lackland D., **Kneuper Hall R.**, et. al. Higher Birth Weights May Be Related to Increased Risk of Aggressive Breast Cancer in Young African-American Women. *Breast Cancer Research and Treatment*. November, 2001.
14. Baker MK, Mikhitarian K, Osta W, Callahan K, Hoda R, Brescia F, **Kneuper Hall R**, Mitas M, Cole DJ, and Gillanders WE. Molecular Detection of Breast Cancer Cells in the Peripheral Blood of Advanced-Stage Breast Cancer Patients Using Multimarker Real-Time Reverse Transcription-Polymerase Chain Reaction and a Novel Porous Barrier Density Gradient Centrifugation Technology. *Clinical Cancer Research* 9: 4865-4871, October, 2003.
15. Mainous III AG, Kern D, Hainer B, **Kneuper Hall R**, Stephens J, Geesey M. The Relationship Between Continuity of Care and Trust With Stage of Cancer at Diagnosis. *Family Medicine Journal* Volume 36 Issue 1: 35-39. January, 2004.
16. Skorupa A, Metzner-Sadurski J, Wolff D, Gupta R, **Kneuper Hall R**. HER-2/Neu Amplified Breast Cancers In South Carolina. *The Journal of the South Carolina Medical Association* Volume 101 97-99. April 2005.
17. Brown R, Fuemmeler B, Anderson D, Jamieson S, Simonian S, **Kneuper Hall R**, Brescia F. Adjustment of Children and Their Mothers with Breast Cancer. *Mothers with Breast Cancer*. July 2005.
18. Cady F, **Kneuper Hall R**, Metcalf J. Histologic Patterns of Polyethylene Glycol (PEG) – Liposomal Doxorubicin-Related Cutaneous Eruptions. (In Press)
19. McDonnell A, **Kneuper Hall R**. Acute Generalized Exanthematous Pustulosis Due to Letrozole. (In Press)
20. Benz CC, Fedele V, Tseng FX, Ylstra B, Ginzinger D, Yu M, Moore D, Scott GK, **Kneuper Hall R**, Wolff D, Disis ML, Eppenberger-Castori S, Eppenberger U, Tommasi S, Paradiso A, and Albertson DG. Altered Promoter Usage Characterizes Monoallelic Transcription Arising with ERBB2 Amplification in Human Breast Cancers (Submitted to *Genes Chromosomes and Cancer*.)